ES3048688T3 - High dosage strength tablets of rucaparib - Google Patents
High dosage strength tablets of rucaparibInfo
- Publication number
- ES3048688T3 ES3048688T3 ES15833096T ES15833096T ES3048688T3 ES 3048688 T3 ES3048688 T3 ES 3048688T3 ES 15833096 T ES15833096 T ES 15833096T ES 15833096 T ES15833096 T ES 15833096T ES 3048688 T3 ES3048688 T3 ES 3048688T3
- Authority
- ES
- Spain
- Prior art keywords
- tablet
- rucaparib
- tablet according
- formulations
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040849P | 2014-08-22 | 2014-08-22 | |
| US201562101739P | 2015-01-09 | 2015-01-09 | |
| PCT/US2015/045522 WO2016028689A1 (en) | 2014-08-22 | 2015-08-17 | High dosage strength tablets of rucaparib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3048688T3 true ES3048688T3 (en) | 2025-12-11 |
Family
ID=55347324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15833096T Active ES3048688T3 (en) | 2014-08-22 | 2015-08-17 | High dosage strength tablets of rucaparib |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9987285B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3182975B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6574477B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20170043597A (cg-RX-API-DMAC7.html) |
| CN (2) | CN106794185A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015305696B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017000865A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2955495C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3182975T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3048688T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3182975T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL249946B (cg-RX-API-DMAC7.html) |
| LT (1) | LT3182975T (cg-RX-API-DMAC7.html) |
| MX (1) | MX367260B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ728392A (cg-RX-API-DMAC7.html) |
| PT (1) | PT3182975T (cg-RX-API-DMAC7.html) |
| RS (1) | RS67356B1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2705156C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201700265VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016028689A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| KR20220136460A (ko) | 2014-02-05 | 2022-10-07 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
| LT3182975T (lt) * | 2014-08-22 | 2025-11-25 | Tabletės su didele rukaparibo doze | |
| CN106008530B (zh) * | 2016-07-24 | 2018-06-26 | 石家庄久正生物科技有限公司 | 一种抗卵巢癌药物Rucaparib关键中间体的制备方法 |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| HRP20241280T1 (hr) | 2017-01-24 | 2024-12-06 | Assia Chemical Industries Ltd. | Kruti oblici rukapariba i soli rukapariba |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| EA202090573A1 (ru) * | 2017-09-26 | 2020-09-07 | Тесаро, Инк. | Составы нирапариба |
| WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
| PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN109111454A (zh) * | 2018-08-01 | 2019-01-01 | 宁波金未生物科技有限公司 | 一种瑞卡帕布s-樟脑磺酸盐 |
| CN108853030B (zh) * | 2018-09-26 | 2021-10-01 | 上海朝晖药业有限公司 | 一种治疗恶性肿瘤的药物制剂及其制备方法 |
| CN111542527A (zh) | 2018-12-06 | 2020-08-14 | 上海诚妙医药科技有限公司 | 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途 |
| JP7675060B2 (ja) | 2019-07-10 | 2025-05-12 | サイブレクサ ３，インコーポレイテッド | 治療薬としての微小管標的化剤のペプチドコンジュゲート |
| CR20220058A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos |
| CA3176206A1 (en) | 2020-04-28 | 2021-11-04 | Debnath Bhuniya | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| WO2022015557A1 (en) | 2020-07-14 | 2022-01-20 | Assia Chemical Industries Ltd | Solid state forms of rucaparib salts |
| AU2021319090A1 (en) | 2020-07-29 | 2023-03-02 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| WO2022140537A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2023011793A (es) | 2021-04-08 | 2023-10-12 | Rhizen Pharmaceuticals Ag | Inhibidores de poli(adenosin difosfato-ribosa) polimerasa. |
| WO2023049920A1 (en) | 2021-09-27 | 2023-03-30 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| EP4429636A1 (en) * | 2021-11-10 | 2024-09-18 | Crititech, Inc. | Rucaparib particles and uses thereof |
| EP4463232A1 (en) | 2022-01-11 | 2024-11-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2218110T3 (es) | 1999-01-11 | 2004-11-16 | Agouron Pharmaceuticals, Inc. | Inhibidores triciclicos de poli(adp-ribosa)polimerasas. |
| WO2004087713A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| DK1660095T3 (da) | 2003-07-25 | 2010-05-25 | Cancer Rec Tech Ltd | Tricykliske PARP-inhibitorer |
| MX2007003314A (es) | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| ATE551345T1 (de) | 2004-09-22 | 2012-04-15 | Pfizer | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
| RU2344138C2 (ru) | 2004-09-22 | 2009-01-20 | Пфайзер Инк. | Способ получения ингибиторов поли(адф-рибоза)полимераз |
| AU2009235426A1 (en) | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
| JP5745283B2 (ja) | 2010-02-12 | 2015-07-08 | ファイザー・インク | ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体 |
| DK2833973T3 (en) * | 2012-04-05 | 2018-01-02 | Vertex Pharma | Compounds useful as ATR kinase inhibitors and combination therapies thereof |
| LT3182975T (lt) | 2014-08-22 | 2025-11-25 | Tabletės su didele rukaparibo doze |
-
2015
- 2015-08-17 LT LTEPPCT/US2015/045522T patent/LT3182975T/lt unknown
- 2015-08-17 JP JP2017510539A patent/JP6574477B2/ja active Active
- 2015-08-17 KR KR1020177007284A patent/KR20170043597A/ko not_active Ceased
- 2015-08-17 WO PCT/US2015/045522 patent/WO2016028689A1/en not_active Ceased
- 2015-08-17 US US14/828,065 patent/US9987285B2/en active Active
- 2015-08-17 MX MX2017001540A patent/MX367260B/es active IP Right Grant
- 2015-08-17 EP EP15833096.9A patent/EP3182975B1/en active Active
- 2015-08-17 KR KR1020237020594A patent/KR102803917B1/ko active Active
- 2015-08-17 RS RS20251082A patent/RS67356B1/sr unknown
- 2015-08-17 NZ NZ728392A patent/NZ728392A/en unknown
- 2015-08-17 AU AU2015305696A patent/AU2015305696B2/en active Active
- 2015-08-17 CA CA2955495A patent/CA2955495C/en active Active
- 2015-08-17 ES ES15833096T patent/ES3048688T3/es active Active
- 2015-08-17 RU RU2017109139A patent/RU2705156C2/ru active
- 2015-08-17 FI FIEP15833096.9T patent/FI3182975T3/fi active
- 2015-08-17 BR BR112017000865A patent/BR112017000865A2/pt not_active Application Discontinuation
- 2015-08-17 SG SG11201700265VA patent/SG11201700265VA/en unknown
- 2015-08-17 CN CN201580042815.9A patent/CN106794185A/zh active Pending
- 2015-08-17 CN CN202110458329.2A patent/CN113209033A/zh active Pending
- 2015-08-17 PT PT158330969T patent/PT3182975T/pt unknown
- 2015-08-17 DK DK15833096.9T patent/DK3182975T3/da active
-
2017
- 2017-01-05 IL IL249946A patent/IL249946B/en active IP Right Grant
-
2018
- 2018-03-14 US US15/920,643 patent/US10130636B2/en active Active
- 2018-10-08 US US16/154,038 patent/US20190099430A1/en not_active Abandoned
-
2019
- 2019-08-15 JP JP2019149084A patent/JP6797980B2/ja active Active
- 2019-11-29 AU AU2019272064A patent/AU2019272064B2/en active Active
-
2020
- 2020-11-18 JP JP2020191356A patent/JP7127101B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3048688T3 (en) | High dosage strength tablets of rucaparib | |
| EP3606511B1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
| KR20140087846A (ko) | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 | |
| US8951504B2 (en) | (trimethoxyphenylamino) pyrimidinyl formulations | |
| TWI418370B (zh) | 溶出安定性製劑 | |
| US20070172521A1 (en) | Levetiracetam formulations and methods for their manufacture | |
| JP2017520619A (ja) | セリチニブ製剤 | |
| HK1232807A1 (en) | High dosage strength tablets of rucaparib | |
| HK1232807B (en) | High dosage strength tablets of rucaparib | |
| JP2019014700A (ja) | エゼチミブ含有口腔内崩壊錠及びその製造方法 | |
| KR20160085241A (ko) | 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법 |